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Abstract 
The ETV6 gene located at band 12p13 encodes a 
protein containing two major domains, the HLH 
(helix-loop-helix) domain, encoded by exons 3 and 
4, and the ETS domain, encoded by exons 6 
through 8, with in between the internal domain 
encoded by exon 5. ETV6 is a strong transcriptional 
repressor, acting through its HLH and internal 
domains. Five potential mechanisms of ETV6-
mediated carcinogenesis have been identified: 
constitutive activation of the kinase activity of the 
partner protein, modification of the original 
functions of a transcription factor, loss of function 
of the fusion gene, affecting ETV6 and the partner 
gene, activation of a proto-oncogene in the vicinity 
of a chromosomal translocation and dominant 
negative effect of the fusion protein over 
transcriptional repression mediated by wild-type 
ETV6. Thirty-three ETV6 partner genes have been 
identified. 
Identity 
Other names: TEL, TEL1 
HGNC (Hugo): ETV6 
Location: 12p13.2 
 
ETV6 (12p13.2) in normal cells: clone dJ852F10 - 




A member of the ets (E-26 transforming specific) 
family of transcription factors; the gene spans a 
region of 240 kb and consists of 8 exons. There are 
two start codons, one (exon 1a starting at codon 1) 
located at the beginning of the gene and another 
alternative (exon 1b starting at codon 43) upstream 
of exon 3. 
Transcription 
Transcription is from telomere to centromere; there 
are three species of transcripts : 2400 kb, 4300 kb 
and 6200 kb; the gene encodes for a 1356 kb 
cDNA. 
 
Schematic diagram of the ETV6 gene showing the 8 exons. Exon 1b is an alternative exon located in intron 2. Reprinted from 
Leukemia Research, vol 36, De Braekeleer E et al. ETV6 fusion genes in hematological malignancies: A review. Pages 945-961, 
2012. With permission from Elsevier. 
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Schematic diagram of the ETV6 protein showing the major domains. Reprinted from Leukemia Research, vol 36, De 






The ETV6 protein is a 452 amino acid polypeptide 
that shares homology at the 5' and 3' ends with 
other ETS family members. ETS proteins form one 
of the largest families of signal-dependent 
transcriptional regulators, mediating cell 
proliferation, differentiation and tumorigenesis.  
The ETV6 protein contains two major domains, the 
HLH (helix-loop-helix) and ETS domains.  
The HLH domain, also referred to as the pointed or 
sterile alpha motif domain, is encoded by exons 3 
and 4 and is responsible for hetero- and 
homodimerization with other ETV6 proteins and 
possibly other ets family members.  
The ETS domain, encoded by exons 6 through 8, is 
responsible for sequence specific DNA-binding and 
protein-protein interaction. A central domain, called 
internal domain, is encoded by exon 5 and is 
involved in the recruitment of a repression complex 
including N-Cor, mSin3 and SMRT. 
Expression 
Expression arrays and Northern analysis have 
shown ubiquitous expression with greater 
expression in bone marrow, spleen and thymus. 
Localisation 
Immunofluorescence has shown a nuclear 
localization. 
Function 
The ETV6 protein plays a crucial role in the 
embryonic development and hematopoietic 
regulation.  
 
ETV6 is essential for normal development and is 
specifically required for maintaining blood vessel 
integrity within the developing yolk sac and 
survival of different cell types in the developing 
embryo.  
ETV6 is essential for the establishment of 
hematopoiesis of all lineages in the bone marrow. 
ETV6 is a strong transcriptional repressor. 
Repression is mediated by the HLH domain and the 
internal domain.  
Repression by the HLH domain is mediated 
through interaction with the HLH domain of 
L3MBTL1, a member of the polycomb group of 
chromatin-associated proteins, that can maintain 
long term repression of genes through a histone 
deacetylase-independent mechanism.  
Repression by the internal domain is mediated 
through interaction with corepressors such as N-




ETV6 is implicated in leukemia, myelodysplastic 
syndromes and sarcoma. 
Deletions: ETV6 is frequently deleted in 
hematological malignancies.  
The deletion of the normal (untranslocated) ETV6 
allele in the presence of a translocation affecting 
ETV6 is quite frequent, notably in patients with 
ETV6-RUNX1, ETV6-NTRK3, ETV6-ABL1, 
ETV6-ACSL6 and ETV6-STL fusion.  
Deletion of an ETV6 allele has also been observed 
in the absence of rearrangement of the second 
allele. 
 










One CML with t(9;22) (no molecular analysis) and 
one refractory anemia with excess of blasts in 
transformation. 
Abnormal protein 
Truncated ETV6 protein lacking critical functional 
domains and suggesting a loss of function of ETV6. 
Oncogenesis 
Loss of function of ETV6? Expression of RPL11, 
centromeric to MDS2 (63.5 kb) much higher in the 
patient than in controls. 
t(1;12)(q21;p13) ARNT/ETV6 
Disease 
One AML-M2 and one T-cell acute lymphoblastic 
leukemia. 
Hybrid/Mutated gene 
The ETV6-ARNT transcript contains the first 4 
exons of ETV6 fused in frame with exon 1 or 2 of 
ARNT. 
Abnormal protein 
The ETV6-ARNT protein contains the 
oligomerization domain of ETV6 and almost all of 
the ARNT protein, including its major domains. 
Oncogenesis 
Given the presence of the oligomerization domain 
of ETV6 in the ETV6-ARNT protein, it is expected 
that the HLH domain of ETV6 convert ARNT from 
a transcriptional activator into a repressor. 
Furthermore, the ETV6-ARNT fusion protein 
retaining the HLH domain of ETV6 could interact 
with the other ETV6 protein. 
t(1;12)(q25;p13) ABL2/ETV6 
Disease 
AML-M3, AML-M4, T-cell ALL, B-cell ALL. 
Hybrid/Mutated gene 
Breakpoint in intron 5 of ETV6 in all three cases. 
Abnormal protein 
Fusion protein contains the HLH oligomerization 
domain of ETV6 and the SH2, SH3, and protein 
tyrosine kinase domains of ABL2. 
Oncogenesis 





Rare, but recurrent, chromosomal aberration (more 
than 30 cases). Few patients studied on a molecular 
level. 
Disease 
Myeloproliferative disorders, myelodysplastic 
syndromes and acute myelogenous leukemia. 
Hybrid/Mutated gene 
Two different mechanisms for generating the fusion 
gene. 
First mechanism: in-frame chimeric transcript 
consisting of the first two exons of ETV6 fused to 
MDS1 sequences, which in turn is fused to the 
second exon of the EVI1 gene. 
Second mechanism: direct fusion between ETV6 
and EVI1, in which case an out-of-frame fusion 
between exon 2 of ETV6 and exon 2 of EVI1 is 
generated but the open reading frame of EVI1 is not 
disrupted. 
Abnormal protein 
In both fusion types, ETV6 contributes no known 
functional domain to the predicted chimeric protein. 
Oncogenesis 
Oncogenic potential of the translocation could be 
the result of the ETV6 promoter driving the 
transcription of EVI1, resulting in activation of the 
transcription factor EVI1, which is not normally 
expressed in hematopoietic cells. 
t(4;12) (p16;p13) FGFR3/ETV6 
Disease 
Peripheral T-cell lymphoma 
Hybrid/Mutated gene 
Fusion of exon 5 of ETV6 to exon 10 of FGFR3. 
Abnormal protein 
Protein consists of the HLH domain of ETV6 and 
the tyrosine kinase domain of FGFR3. 
Oncogenesis 
Constitutive activation of the kinase activity of 
FGFR3. 
t(4;12)(q11;p13) CHIC2 (BTL)/ETV6 
Note 
Rare but recurrent chromosomal abnormality. Ten 
cases with molecular analysis showed a 
CHIC2/ETV6 fusion gene. 
Disease 
AML (FAB type M0, M1, M2, therapy-related), 
RAEB. 
Hybrid/Mutated gene 
At least two different mechanisms. 
First mechanism: In-frame fusion between CHIC2 
exons 1-3 and exons 2-8 of the ETV6 gene. 
Second mechanism: Breakpoints located in introns 
1 and 2 of ETV6 but outside the CHIC2 gene, with 
no detectable CHIC2-ETV6 fusion gene. 
Abnormal protein 
Fusion protein contains both the HLH and ETS 
domains of ETV6 but no specific domain of 
CHIC2. 
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Oncogenesis 
Ectopic expression of GSX2 detected in all cases 
studied, with or without the CHIC2-ETV6 fusion. 
GSX2 contains a homeobox domain very similar to 
the homeobox of the clustered HOX genes, which 
are involved in both normal and abnormal 
hematopoiesis. Overexpression of GSX2, but not 
CHIC2-ETV6 has transforming properties. 
t(5;12)(q31;p13) ACSL6/ETV6 
Note 
Recurrent translocation occurring in various 
myeloid malignancies, often associated with 
eosinophilia. Only seven cases with molecular 
analysis. 
Disease 
Myelodysplastic syndrome (RAEB), AML, AEL, 
atypical CML, Polycythemia Vera. 
Hybrid/Mutated gene 
Different fusion genes are generated in four 
patients: 
- in-frame fusion of exon 1 of ETV6 to the 3'UTR 
of ACSL6 
- out-of-frame fusion of exon 2 of ETV6 to exon 11 
of ACSL6 
- out-of-frame fusion of exon 1 of ETV6 to exon 1 
of ACSL6 
- in-frame fusion of exon 1 of ETV6 to almost the 
complete ACSL6 (breakpoint at the 5' end of the 
ACSL6 gene). 
Oncogenesis 
Given the absence of a common in-frame fusion 
gene generated by the t(5;12)(q31;p13) and the 
heterogeneity in the localization of the ACSL6 
breakpoints, no common fusion protein can explain 
the pathogenic character of the translocation. IL3, 
located near the breakpoint at 5q31, is ectopically 








(usually referred as atypical Philadelphia-negative 
CML and CMML) with eosinophilia. 
Hybrid/Mutated gene 
Exon 4 of the ETV6 gene is generally fused in-
frame to exon 11 of the PDGFRB gene. 
Two cases showing a different fusion gene with the 
ETV6 breakpoint in intron 7. 
Abnormal protein 
Protein includes the HLH domain of ETV6 and the 
tyrosine kinase domain of PDGFRB. 
In both cases showing a different fusion gene, the 
fusion protein retains the internal domain of ETV6 
which has the ability to bind to corepressors and 
induce the transcription-repressive activity of 
ETV6. 
Oncogenesis 
Constitutive activation of the kinase activity of 
PDGFRB. 
In both cases showing a different fusion gene, it is 
likely that the fusion protein acts differently from 
that observed in the other cases. 
t(6;12)(q23;p13) STL/ETV6 
Note 




Fusion gene only retains the first two exons of 
ETV6. 
Abnormal protein 
Fusion protein contains no important domains 
(HLH or ETS) of ETV6. 
Oncogenesis 
It is likely that the truncated ETV6 contributes to 
leukemogenesis through ETV6 haploinsufficiency. 
t(7;12)(q36;p13) MNX1(HLXB9)/ETV6 
Note 
Recurrent translocation found in 20 to 30% of AML 
children less than 18 months of age. The 7q36 
breakpoint heterogeneity suggests that this 
translocation does not lead to the formation of a 
unique fusion gene. Six cases with molecular 




5' MNX1-3' ETV6 resulting in a transcript in which 
MNX1 exon 1 is joined with ETV6 exon 3. 
Abnormal protein 
Protein contains the HLH and ETS domains of 
ETV6 but not the homeobox domain of MNX1. 
Oncogenesis 
It is thought that the chimeric protein acts as an 
aberrant transcription factor, which could affect 




Nonrandom chromosome abnormality found in 
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Hybrid/Mutated gene 
5'PAX5-3'ETV6 transcript with fusion of exon 4 of 
PAX5 to exon 3 of ETV6. 
Abnormal protein 
The PAX5-ETV6 protein contains the "paired box" 
(DNA binding) domain of PAX5 fused to the HLH 
and ETS-binding domains of ETV6. 
Oncogenesis 
It is thought that the chimeric protein could act as 
an aberrant transcription factor, which could affect 
both PAX5 and ETV6 pathways of transcription 
modulation. 
t(9;12) (p24;p13) JAK2/ETV6 
Note 
Only six cases described with ETV6/JAK2 fusion. 
Disease 
Pre-B ALL, atypical CML, T-cell ALL. 
Hybrid/Mutated gene 
Breakpoint variability: introns 4 and 5 of ETV6 and 
introns 12 and 17 of JAK2. 
Abnormal protein 
Protein retains the HLH domain of ETV6 but 
different domains of JAK2 (complete JH2 and JH1 
in one case, only part of JH2 in the other). 
Oncogenesis 








Chimeric gene fuses the first 5 exons of ETV6 with 
SYK starting with exon 5. 
Abnormal protein 
Fusion protein contains the HLH domain of ETV6 
with part of the C-terminal SH2 and the complete 
protein kinase domain of SYK. 
Oncogenesis 
Constitutive activation of SYK kinase activity. 
t(9;12)(q34;p13) ABL1/ETV6 
Note 
26 cases described with different hemopathies but 
eosinophilia is a common feature. 
Disease 
Acute myeloblastic leukemia (AML), chronic 
myelogenous leukemia (CML), B-cell acute 
lymphocytic leukemia (ALL), T-cell ALL, MDS 
(RAEB), chronic myeloproliferative neoplasm, 
Philadelphia chromosome-negative CML. 
 
Hybrid/Mutated gene 
Two ETV6-ABL1 transcripts are usually identified: 
one joining exon 5 of ETV6 to exon 2 of ABL1 and 
one joining ETV6 exon 4 to ABL1 exon 2. 
Abnormal protein 
The protein retains all three SH domains, including 
the tyrosine kinase domain, of ABL1 and the HLH 
domain of ETV6. 
Oncogenesis 
Tyrosine kinase activation of ABL1. 
t(10;12)(q24;p13) GOT1/ETV6 
Note 
Two cases of MDS described. 
Disease 
MDS (RA and RAEB). 
Hybrid/Mutated gene 
Transcript containing exon 2 to exon 9 of GOT1 
and the first 2 or 3 exons of ETV6. 
Abnormal protein 
Absence or truncation of the HLH domain of ETV6 
in the protein. 
Oncogenesis 
Possibly inactivation of the wild type ETV6. 
t(12;13)(p13;q12) ETV6/CDX2 
Note 
The t(12;13)(p13;q12-14) is a rare, but recurrent, 
translocation reported in a range of malignant 
hemopathies. However, it is evident from FISH 
studies that they are heterogeneous at the molecular 
level. 
Disease 
CML in transformation, myelodysplastic syndrome 
(MDS), acute non lymphocytic leukemia (ANLL), 
B and T- ALL. A sole case with ETV6/CDX2 
fusion in a AML-M1. 
Hybrid/Mutated gene 
One in-frame fusion between exon 2 of ETV6 and 
exon 2 of CDX2; one fusion introducing an in-
frame stop codon. 
Abnormal protein 
ETV6 contributes no functional domain to the 
fusion protein. 
Oncogenesis 
It is likely that the ETV6 promoter drives the 
transcription and ectopic activation of CDX2, 
which has leukemogenesis properties. 
t(12;13)(p13;q14) ETV6/TTL [not 
annotated gene in HGNC] 
Note 
Identified in several cases of ALL and less 
frequently in acute or chronic myeloid 
malignancies. 
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Disease 
A sole case with TTL/ETV6 fusion in a ALL. 
Hybrid/Mutated gene 
ETV6/TTL fusion transcript: 3' TTL sequence 
introduces an in-frame stop codon after the end of 
ETV6 exon 1. 
TTL-ETV6 transcript is a direct in-frame fusion 
between TTL exon 5 and ETV6 exon 2. 
Abnormal protein 
No ETV6 functional domains in the ETV6/TTL 
protein; HLH and ETS domains conserved in TTL-
ETV6 protein. 
Oncogenesis 
Chimeric protein could act as an aberrant 
transcription factor, affecting the ETV6 pathway of 
transcription modulation, or there could be a loss of 
function of ETV6 and/or TTL. 
t(12;15)(p13;q25) ETV6/NTRK3 
Disease 
Congenital Fibrosarcoma, Congenital Mesoblastic 
Nephroma (cellular and mixed variants), Secretory 
Ductal Carcinoma of Breast, rarely in AML (M0, 
M2) and chronic eosinophilia leukemia (1 case). 
Hybrid/Mutated gene 
5' ETV6-3' NTRK3. 
Abnormal protein 
Fusion protein retains the HLH domain of ETV6 
and the protein tyrosine kinase (PTK) domain of 
NTRK3. 
Oncogenesis 
Constitutive active tyrosine kinase. 
t(12;17)(p13;p13) ETV6/PER1 
Disease 
Only one case of AML evolving from CMML. 
Hybrid/Mutated gene 
Fusion between exon 1 of the ETV6 gene and exon 
22 and part of intron 21 of PER1. 
Abnormal protein 
No protein as PER1 has an antisense orientation. 
Oncogenesis 
It is proposed that PER1 inactivation or deregulated 
expression of genes located close to the breakpoint, 




Most common structural chromosomal abnormality 
in pediatric common or B-cell acute lymphoblastic 
leukemia, accounting for about 20-25% of the 
cases. 
Disease 
Childhood B-cell (ALL). 
Hybrid/Mutated gene 
Fusion of the 5' region of ETV6 (from exon 1 to 5) 
with almost the entire coding region of RUNX1. 
Abnormal protein 
The fusion protein retains the HLH domain and the 
central repression domain of ETV6 as well as the 
RHD (Runt homology domain) and the 
transcription activation domain of RUNX1. 
Oncogenesis 
The ETV6-RUNX1 fusion protein retains the 
ability to bind the RUNX1 target sequences and 
functions as a histone deacetylase (HDAC)-
dependent repressor, causing deregulation of the 
RUNX1 target genes. ETV6-RUNX1 is also likely 




Rare anomaly in myeloid hemopathies (6 cases 
with molecular analysis). 
Disease 
Myeloproliferative disorder, myelodysplastic 
syndrome, AML. 
Hybrid/Mutated gene 
Two different types of MN1/ETV6 fusion (types I 
and II). 
Abnormal protein 
Type I fusion protein contains almost the entire 
MN1 fused to ETV6 at a position N terminal to the 
HLH domain whereas type II fusion protein has 
only part of the HLH domain, making it 
nonfunctional. Both fusion types retain the ETS 
domain. 
Oncogenesis 
Could act as an altered transcription factor by 
activating ETV6-responsive transcription and/or 
inhibiting RAR-mediated transcription and/or being 
a dominant-negative suppressor of MN1. 
t(4;12)(q23;p13) ETV6/PDGFRA 
Note 
PDGFRA is a gene found to be fused with several 
partners in chronic eosinophilic leukemia. 
Disease 
Only one case of myeloproliferative neoplasm 
associated with hypereosinophilia and 
ETV6/PDGFRA fusion. 
Hybrid/Mutated gene 
In-frame fusion gene between ETV6 exon 6 and 
PDGFRA exon 11. 
Abnormal protein 
Protein retains most of ETV6, including the HLH 
domain and part of the ETS domain, fused to the 
WW-like domain and the kinase domain of 
PDGFRA. 
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Oncogenesis 
Constitutive protein kinase activation. 
t(12;13)(p13;q12) ETV6/FLT3 
Note 
FLT3 is one of the most frequently mutated genes 
in hematological malignancies, being found in 
about 30% of AML patients and rarely in ALL 
patients. 
Disease 
Three cases of myeloproliferative neoplasm with 
hypereosinophilia associated with ETV6/FLT3 
fusion. 
Hybrid/Mutated gene 
In-frame fusion gene between ETV6 exon 4 or exon 
5 and FLT3 exon 14. 
Abnormal protein 
Protein retains the HLH domain of ETV6 and the 
tyrosine kinase domains of FLT3. 
Oncogenesis 
Constitutively tyrosine kinase activation. 
t(6;12)(q21;p13) ETV6/FRK 
Disease 
Only one case of AML-M4. 
Hybrid/Mutated gene 
ETV6 exon 4 fused in frame to exon 3 of FRK. 
Abnormal protein 
Chimeric protein composed of the HLH domain of 
ETV6 and most of the SH2 (likely to be 
nonfunctional) and the kinase domains of FRK. 
Oncogenesis 
Dual action of constitutively tyrosine kinase 
activation and dominant-negative effect on ETV6-
mediated transcriptional repression. 
ins(12;8)(p13;q11q21) ETV6/LYN 
Disease 
Only one case of primary myelofibrosis associated 
with ETV6/LYN. 
Hybrid/Mutated gene 
Chimeric gene consists of the 5' region of ETV6 
(breakpoint in intron 5) and the 3' region of LYN. 
Abnormal protein 
Protein retains the HLH domain of ETV6 and the 
tyrosine kinase domain of LYN. 
Oncogenesis 
Constitutively tyrosine kinase activation. 
inv(12)(p13q13) ETV6/PTPRR 
Disease 
Only one case of AML-M2 associated with 
ETV6/PTPRR. 
Hybrid/Mutated gene 
ETV6 exon 4 is fused to exon 7 of the PTPRR; 10  
 
isoforms through alternative splicing. 
Abnormal protein 
A truncated ETV6 including the HLH domain but 
no functional domains of PTPRR due to frameshift 
and a chimeric ETV6-PTPRR protein that includes 
the HLH domain of ETV6 and the protein tyrosine 
phosphatase domain of PTPRR among others. 
Oncogenesis 
Dominant negative effect over transcriptional 
repression mediated by wild-type ETV6. 
t(8;12)(q13;p13) ETV6/NCOA2 
Disease 
Pediatric acute biphenotypic leukemia (6 cases with 
ETV6/NCOA2), adult T-ALL (1 case). 
Hybrid/Mutated gene 
Two different in-frame fusions are known: 
- one between ETV6 exon 4 and NCOA2 exon 15 
(five cases) 
- one between ETV6 exon 5 and NCOA2 exon 14 
(one case). 
Abnormal protein 
Protein consists of the HLH domain of ETV6 and 
the CBP interaction and the AD2 (transactivation 
domain 2) acetyltransferase domains of NCOA2. 
Oncogenesis 
It is hypothesized that the ETV6-NCOA2 protein 
acts as a modulator of the transcriptional activity of 
CBP-dependent activators or can recruit CBP to 
ETV6 target genes resulting in their constitutive 
activation. 
Cryptic rearrangement shown by 
FISH between 12p13 and 12q24 
ETV6/BAZ2A in a t(?1;12)(q42;p13) 
Disease 
Only one case of pre-B ALL. 
Hybrid/Mutated gene 
Fusion of ETV6 and BAZ2A consisting of exons 1 
and 2 of ETV6 and a sequence from intron 1 of 
BAZ2A. 
Abnormal protein 
No chimeric protein expected to be produced, but, 
maybe, a truncated ETV6. 
Oncogenesis 
It is likely that the truncated ETV6 contributes to 
leukemogenesis through ETV6 haploinsufficiency. 
t(5;12;22)(q13;p13;q11) ETV6/FCHO2 
Disease 
Only one case of AML-M1. 
Hybrid/Mutated gene 
Transcript consisting of ETV6 exons 1 and 2 with 
sequences of FCHO2. 
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Abnormal protein 
No chimeric protein expected to be produced (genes 
in opposite orientations following the 
translocation), but, maybe, a truncated ETV6. 
Oncogenesis 
It is likely that the truncated ETV6 contributes to 




One case of pediatric pre-B ALL. 
Cytogenetics 
Co-localization of both ETV6 and IGH signals by 
FISH (no molecular analysis). 
t(12;22)(p13;q12) ETV6/EMID1 
Disease 
Only one case of AML-M2. 
Cytogenetics 
Co-localization of both ETV6 and EMID1 signals 
by FISH (no molecular analysis). 
Abnormal protein 
No chimeric protein expected to be produced (genes 
in opposite orientations following the 
translocation), but, maybe, a truncated ETV6. 
t(12;17)(p13;q21) ETV6/RARA 
Disease 
Only one case of myelofibrosis evolved in AML. 
Cytogenetics 
Co-localization of both ETV6 and RARA signals 
by FISH (no molecular analysis). 
Abnormal protein 
No chimeric protein expected to be produced (genes 
in opposite orientations following the 
translocation), but, maybe, a truncated ETV6. 
t(5;12)(p13;p13) NIPBL/ETV6 
Disease 
Only one case of acute megakaryoblastic leukemia 
(AML-M7). 
Cytogenetics 
Co-localization of both ETV6 and NIPBL signals 
by FISH (no molecular analysis). 
Breakpoints 
See figures below. 
 
Chromosomal distribution of the 33 ETV6 partners thus far identified. 
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Physical map of the breakpoint distribution in the ETV6 gene. Yellow boxes: receptor tyrosine kinase genes; orange boxes: 
non-receptor tyrosine kinase genes; red boxes: transcription factor genes; green boxes: homeobox genes; blue boxes: other 
genes. Reprinted from Leukemia Research, vol 36, De Braekeleer E. et al. ETV6 fusion genes in hematological malignancies: A 
review. Pages 945-961, 2012. With permission from Elsevier. 
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